(Q40183302)

18 September 2017

title

The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer (English)

1 reference

18 September 2017

1 reference

1 reference

Capitain O

1

1 reference

18 September 2017

Boisdron-Celle M

2

1 reference

18 September 2017

Poirier AL

3

1 reference

18 September 2017

Abadie-Lacourtoisie S

4

1 reference

18 September 2017

Morel A

5

1 reference

18 September 2017

Gamelin E

6

1 reference

18 September 2017

publication date

14 August 2007

1 reference

The Pharmacogenomics Journal

18 September 2017

published in

1 reference

18 September 2017

volume

8

1 reference

18 September 2017

issue

4

1 reference

18 September 2017

page(s)

256-267

1 reference

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinom

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Fluorouracil: biochemistry and pharmacology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosa

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500476

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500476

1 reference

Dimensions Publication ID

18 September 2017

1001929086

0 references

1 reference